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We have determined the absorption, conjugation and excretion of naringenin-7-O-rutinoside (narirutin) compared to the corresponding
glucoside in an orange juice matrix in human subjects. Healthy volunteers (eight men and eight women), in a double blind, randomised,
crossover study, consumed orange juice with (1) natural content of naringenin-7-O-rutinoside; (2) a-rhamnosidase-treated to yield narin-
genin-7-O-glucoside. Blood was sampled at twelve time points and three fractions of urine were collected over 24 h. The area under the
plasma–time curve of naringenin from (2) a-rhamnosidase-treated orange juice was increased about 4-fold (P,0·0001), peak plasma concen-
tration (Cmax) was 5·4-fold higher (P,0·0001) and Tmax was decreased from 311 to 92 min (P¼0·002) compared to untreated orange juice (1),
indicating a change in absorption site from the colon to the small intestine. Furthermore, the amount in urine was increased from 7 to 47 %
(P,0·0001) of the dose after consumption of the a-rhamnosidase-treated orange juice (2). All urine samples contained both naringenin-7- and
-40-O-glucuronides. In addition, to examine the effect of dose and a-rhamnosidase treatment on hesperetin conjugate profiles, a further treat-
ment where (3) orange juice fortified with three times the original content of hesperetin-7-O-rutinoside was used. Five hesperetin metabolites
(30-O-glucuronide; 7-O-glucuronide; 5,7-O-diglucuronide; 30,7-O-diglucuronide; 30-O-sulphate) were present after all treatments (1–3), with
the same profile of the conjugates. The present data show that bioavailability of naringenin is increased by conversion from rutinoside to
glucoside, but the profile of the conjugates of flavanones formed and excreted in urine is neither affected by the absorption site nor by a
3-fold change in dose.
Naringenin: Hesperetin: Bioavailability: Metabolism: Citrus fruits
Flavanones, hesperetin and naringenin, are abundant in citrus
fruits and constitute a major part of the total flavonoid intake
in many European countries(1,2). Studies on hesperetin and
naringenin have shown several health-protective properties
such as antioxidant and anti-inflammatory action and prevention
of bone loss in vivo (3 – 7). Hesperetin and naringenin are
naturally present in citrus fruits as their respective 7-O-
rutinosides, hesperidin and narirutin(8) (Table 1). By enzymatic
treatment with a-rhamnosidase, the rutinoside moiety
(rhamnose-glucose) can be hydrolysed to yield hesperetin-
7-O-glucoside and naringenin-7-O-glucoside, respectively(9).
The sugar moiety is a major determinant of the absorption
site and bioavailability of the flavonoid since flavonoid
monoglucoside bioavailability is several fold higher than
flavonoid rutinosides(9 – 11). Flavonoid monoglucosides are
absorbed in the small intestine after hydrolysis by lactase
phloridzin hydrolase(12,13) or cytosolic b-glucosidases(14,15),
whereas flavonoid rutinosides must reach the microflora
in the colon before they can be hydrolysed and absorbed.
Both small intestine and colonic epithelium can metabolise
flavonoids via phase 2 conjugation by addition of glucuronic
acid or sulphate groups(16) However, the possibly different
roles of these two tissues are not clear for flavonoid conju-
gation, although it has been recently reported for phenolic
acids(17). The endogenously produced metabolites are at
least in part responsible for the systemic effects of flavo-
noids, and knowledge about the nature of the metabolites
produced is therefore crucial for further studies on putative
health effects. The removal of the rhamnose sugar gives an
ideal system for studying the effect of small intestine and
colon absorption on the metabolic pathways. We demon-
strated that the bioavailability of hesperetin was increased
when hesperidin in orange juice was enzymatically trans-
formed into hesperetin-7-O-glucoside(9). Here, we further
investigate if this enzymatic treatment, as a tool to investigate
the absorption mechanism of hesperidin, could also affect the
*Corresponding author: Gary Williamson, fax þ44 113 343 2982, email g.williamson@leeds.ac.uk
Abbreviations: AUC, area under the curve; DAD, diode array detector.
British Journal of Nutrition (2010), 103, 1602–1609 doi:10.1017/S0007114509993679
q The Authors 2010
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509993679
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 13:44:06, subject to the Cambridge Core terms of use, available at
bioavailability of naringenin and identify the major hesperetin
and naringenin metabolites excreted in urine after absorption
targeted either to the small intestine or colon.
Materials and methods
Study design
The study was conducted as previously described(9). Sixteen
healthy volunteers (eight men and eight women) completed
a double blind, placebo controlled, randomised, three-
treatment crossover study. After an overnight fast, the subjects
were randomly assigned to one of the following three
treatments of orange juice: (1) orange juice naturally
containing 2 and 0·83 mg/kg body weight hesperidin and
narirutin, respectively; (2) a-rhamnosidase-treated orange
juice providing 1·52 and 0·52 mg/kg body weight hesperetin-
7-O-glucoside and naringenin-7-O-glucoside, respectively;
(3) hesperidin-fortified orange juice providing 6 mg/kg body
weight total hesperidin, for metabolite identification (all
values are based on the dose of aglycone equivalents).
Samples of blood (4·5 ml) were collected at 0·5, 1, 1·5, 2, 3,
4, 5, 6, 7, 8, 9 and 10 h after consumption. Urine was collected
just before treatment and in three different fractions: 0–5;
5–10; 10–24 h. Treatments were separated by no less than
a 3-d washout period. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects/patients
were approved by the Ethical Committee of Nestle´ (Lausanne,
Switzerland; protocol 03.15MET). Written consent was
obtained from all subjects.
Chemicals
Orange juice was obtained from Nestle´ (Bangkok, Thailand).
Hesperidinase (67 000 units/g) was from Amano Enzyme
Co., Nagoya, Japan. The isotopically labelled internal
standards, 13C3 daidzein and
13C3 O-desmethylangolensin,
were purchased from the School of Chemistry, University
of St Andrews, St Andrews, UK. The naringenin-7-O-glucoside
and narirutin standards were both purchased from
Extrasynthese, Genay, France. Purity of the compounds was
determined to be 88–90 % using weight and spectrophotometry.
The flavanone standards, hesperetin and naringenin, were
obtained from Sigma Chemicals Co., St Louis, MO, USA.
The enzymes used for enzymatic hydrolysis of meta-
bolites for calibration curves were b-glucuronidase expressed
in Escherichia coli (0·14 mmol/min per mg; Roche Diagnostics,
Mannheim, Germany) and Aerobacter aerogenes sulphatase
(0·0025 mmol/min per mg protein; Sigma-Aldrich). All other
reagents and solvents were HPLC grade.
Naringenin analysis in orange juice, plasma and urine
Naringenin-7-O-glucoside and narirutin were extracted from
orange juice essentially as described previously(18) but without
hydrolysis. Aliquots of 5 ml juice were centrifuged (3000 rpm,
10 min) and applied to Bond Elute columns (2 g; Varian,
Middelburg, The Netherlands). The pellet was subsequently
extracted twice with 5 ml 1 % aqueous formic acid and three
times with 5 ml methanol. The total volume after elution
with methanol was 30 ml. Aliquots of 200ml were evaporated,
reconstituted (0·5 % aqueous acetic acid, 10 % acetonitrile)
Table 1. Structures of hesperetin and naringenin glycosides and their metabolites
3′
4′
5
7 O
O
R3
R4
R1
R2
Compound name Number R1 R2 R3 R4
Hesperetin I OH OH OH CH3
Naringenin II OH OH H OH
Hesperidin III O-Glc-Rha OH OH CH3
Narirutin IV O-Glc-Rha OH H OH
Hesperetin-7-O-glucoside V O-Glc OH OH CH3
Naringenin-7-O-glucoside VI O-Glc OH H OH
Hesperetin-30-O-glucuronide VII OH OH O-GlcU CH3
Hesperetin-7-O-glucuronide VIII O-GlcU OH OH CH3
Hesperetin-5,7-O-diglucuronide IX O-GlcU O-GlcU OH CH3
Hesperetin-30,7-O-diglucuronide X O-GlcU OH O-GlcU CH3
Hesperetin-30-O-sulphate XI OH OH O-SO23 CH3
Naringenin-40-O-glucuronide XII OH OH H O-GlcU
Naringenin-7-O-glucuronide XIII O-GlcU OH H OH
O-Glc-Rha, O-glucose-rhamnose (O-rutinoside); O-GlcU, O-glucuronide.
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and analysed on the HPLC–UV–MS system with diode array
detector (DAD) as described previously(19). The method
of analysis was as reported(9) with minor modifications.
Eluents: A, 0·5 % aqueous acetic acid, 10 mM-ammonium
acetate (v/v); B, acetonitrile. Negative electrospray ionisation
mass spectra were obtained in selected ion monitoring
mode. Conditions for electrospray ionisation: gas temperature,
3508C; drying gas, 12 litres/min; nebuliser pressure, 414 kpa;
capillary voltage (negative), 3500 V. Calibration curves
for naringenin-7-O-glucoside and narirutin were obtained
by spiking orange juice (1) (natural content of hesperetin
and naringenin rutinosides) with 3·5, 7, 14 and 21mM-
naringenin-7-O-glucoside standard and (2) a-rhamnosidase-
treated orange juice with 10, 20, 30 and 40mM-narirutin
as standard, respectively. The spiked juice samples were
extracted and analysed exactly the same way as the samples.
Analysis of hesperetin in orange juice and the concentration
of naringenin aglycone in urine and plasma were determined
as previously described for hesperetin(9).
Identification of hesperetin and naringenin
metabolites in urine
Initially, the identity of metabolites was established on the
basis of their MS spectra. Where possible, the exact sites
of conjugation were subsequently determined by 1H NMR
data after isolation (by collecting fractions directly from the
HPLC), differential spectrophotometry and by comparison of
their HPLC retention times with authentic synthetic standards.
The chemical synthesis of hesperetin conjugates will be
published elsewhere.
NMR spectroscopy. NMR spectra were acquired on
a Bruker AV 400 WB spectrometer (Bruker, Rheinstetten,
Germany) operating at 400·13 MHz for 1H. A 1 mm triple-
resonance inverse probe was used (1H observe, 13C, 77Se
decouple). Samples were dissolved min 10ml d6-dimethyl
sulphoxide and transferred to 1 mm NMR tubes.
Typical parameters: 32 768 points were acquired in the time
domain with a sweep width of 6000 Hz. The 908 pulse was
5·7ms. For suppression of the signal from residual water
from the freeze-drying process and from d6-dimethyl sulph-
oxide, a 1D-noesypresat (Bruker pulse programme library)
pulse sequence was used with a pre-saturation time of 1 s,
mixing time of 0·3 s and decoupler power level of 70 dB.
Receiver gain and number of acquired transients were adjusted
according to sample amount and amount of residual formate
(from the HPLC mobile phase). Typically, thirty-two transi-
ents were acquired for standards and between 2048 and
32 900 for samples.
Spectra were zero-filled to 131 072 complex data points
and processed with an exponential multiplication corres-
ponding to an increase in line width of 1 Hz. Spectra were
interpreted by comparison with authentic non-metabolised
standards.
Identification of hesperetin-30-O-sulphate. The hesperetin-
sulphate in urine samples did not respond well to
enzymatic hydrolysis with sulphatase and it was not possi-
ble to get a clear spectrum with NMR analysis. Instead,
its identity as a hesperetin monosulphate was confirmed
by high-resolution LC–quadrupole time-of-flight (Bruker
Daltonics, Bremen, Germany) analysis. The monoisotopic
mass of hesperetin-sulphate (382·0359 Da) was detected with
a mean error of 1·4 parts per million, and information on the
position of conjugation was determined indirectly by differen-
tial pH spectrophotometry(20). Urine samples were analysed on
HPLC–DAD as described earlier. However, to obtain pH 6
and 8, a constant delivery of 0·055 and 0·1 ml/min 1 M-Tris
base, respectively, was applied to the gradient post-column.
UV detection was carried out at 280 and 330 nm, with peak
scanning between 210 and 600 nm (2 nm steps).
Analysis and quantification of hesperetin and naringenin
metabolites in urine
Urine samples were filtered through a 0·2mm filter and
portioned into aliquots of 200ml. An internal standard mix
(10ml, 13C3 daidzein and
13C3 O-desmethylangolensin,
25 ng/ml dimethyl sulphoxide) was added before adjusting to
approximately pH 3 with 10 % aqueous acetic acid. A total
volume of 220ml was analysed on HPLC–DAD–MS.
UV detection was carried out at 280 nm with peak scanning
between 210 and 600 nm (2 nm steps). UV quantification
was preferred due to tendencies to ion suppression in MS,
and metabolites were quantified on the basis of their UV
absorption unless otherwise stated.
Hesperetin-7-O-glucuronide and hesperetin-30-O-glucuro-
nide were quantified with calibration curves of their respective
authentic synthetic standards (chemical synthesis to be
reported elsewhere). For hesperetin-sulphate-glucuronide
estimation, urine samples were evaporated and reconstituted
in solvent (pure water adjusted to pH 5 with acetic acid).
Calibration curves were made by diluting 1:1 in solvent four
times in duplicate, resulting in two calibration curves with
four concentrations (100, 50, 25 and 12·5 %). To the samples
in one calibration curve were added 3ml b-glucuronidase,
20ml sulphatase and 5ml internal standard (20 ng 13C
daidzein/ml dimethyl sulphoxide), and to the samples in the
other calibration curve were added 23ml solvent and 5ml
internal standard. All samples were left at 378C for 1 h.
Before analyses on HPLC–DAD–MS, all samples were
added to 25ml 0·5 % acetic acid and 25ml methanol and
centrifuged (10 000 rpm, 5 min). Hesperetin aglycone
calibration curves were analysed along with the hydrolysed
and unhydrolysed calibration curves for estimation of
hesperetin-sulphate-glucuronide.
Calibration curves for naringenin-7- and -40-O-glucuronide
were obtained similar to hesperetin-sulphate-glucuronide
as described earlier, except no sulphatase was added, and
naringenin aglycone calibration curves were analysed along
with the hydrolysed and unhydrolysed calibration curves. Due
to co-eluting compounds, naringenin-7- and -40-O-glucuronide
could not be quantified on the basis of UV data but were
quantified from MS data.
For analysis of hesperetin-30-O-sulphate, urine was evapor-
ated and reconstituted in 0·1 M-HCl. Calibration curves were
then made by diluting 1:1 five times in duplicate. For one
calibration curve, 80ml of sodium acetate (2 M) was added
resulting in a pH of about 5 and a total volume of 130ml
and left at room temperature for 1 h. For the other calibration
curve (total volume 50ml), samples were heated to 958C for
1 h. Before HPLC–DAD–MS analysis, the heated samples
were added to 10ml of acetonitrile and 40ml of pure water,
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while the samples left at room temperature were added to
20ml of acetonitrile.
Hesperetin aglycone calibration curves were analysed along
with the hydrolysed and unhydrolysed calibration curves.
Correlation coefficients of all calibration curves were .0·99.
Statistics
The incremental area under the curve (AUC) was determined
by a mixed log-linear trapezoidal model, where the linear rule
(trapezoidal) is applied to the range where concentration is
ascending and the log-linear rule is applied to the range
where concentration is descending. Combination of the two
trapezoidal methods enhances the estimation of the AUC
in reducing errors inherent to both methods by applying
them under the conditions of best estimate. Values below
the limit of quantification were set to limit of quantification
(plasma naringenin limit of quantification ¼ 0·0037mmol/l).
To compare groups 1 and 2, no adjustment for multiplicity
was used and all tests were performed at a level 5 %. AUC,
Cmax and Tmax were calculated using Kinetica (Innaphase,
Philadelphia, PA, USA); all other statistical analyses were
done with SAS software (version 8.2; SAS Institute, Inc.,
Cary, NC, USA). From 1 week before the intake of the first
treatment, subjects were randomly allocated to one of the
three different sequences from the Latin square: [A]–[B]–[C];
[B]–[C]–[A]; [C]–[A]–[B]. The randomisation was done
on age and with BMI as the balancing factor.
Results
Plasma bioavailability of total naringenin as aglycone
(area under the curve)
The AUC for total plasma naringenin (Fig. 1) after subjects
consumed the a-rhamnosidase-treated orange juice (2) was
about 4-fold higher compared with consumption of the
untreated orange juice (1) and Cmax was 5·4-fold higher
(Table 2).
Intake and urinary excretion of naringenin
(as aglycone equivalents)
The total naringenin excretion over 24 h was calculated by
pooling the three fractions of urine collected, and the data
were expressed as a percentage of naringenin intake.
The relative urinary excretion of total naringenin of the
subjects was significantly higher (6·7-fold) after consuming
a-rhamnosidase-treated orange juice (2) than after consump-
tion of untreated orange juice (1) (Table 2).
Hesperetin and naringenin metabolites excreted in urine
The consumption of orange juice containing the natural
untreated dose of hesperidin and narirutin (1), hesperetin-
7-O-glucoside and naringenin-7-O-glucoside (2) or high
dose of hesperidin (3) resulted in the detection of a total of
six urinary metabolites of hesperetin and two metabolites of
naringenin by HPLC–MS (Fig. 2). NMR analysis allowed
the structural elucidation of four of the six hesperetin and
two naringenin metabolites in human urine (Table 3).
The identified hesperetin metabolites were: hesperetin-
30-O-glucuronide; hesperetin-7-O-glucuronide; hesperetin-5,
7-O-diglucuronide; hesperetin-30,7-O-diglucuronide. The sub-
stitution position of hesperetin-30-O-sulphate was identified by
differential pH spectrophotometry. In addition, a hesperetin-
sulphate-glucuronide was detected, but it was not possible
to specify the exact substitution positions. Hesperetin-
sulphate-glucuronide was identified by MS fragmentation
patterns and by enzymatic hydrolysis with sulphatase and
glucuronidase which required both enzymes to generate the
aglycone. Hesperetin-7- and -30-O-glucuronides were con-
firmed by comparison with synthetic standards. Hesperetin-
5,7-O-diglucuronide and hesperetin-7,30-O-diglucuronide
were not quantified due to insufficient amounts. The limit of
quantification of these diglucuronides could not be accurately
determined, since no standards are available. The naringenin
metabolites were naringenin-7-O- and -40-O-glucuronide.
Hesperetin and naringenin metabolites were quantified in
urine collected at the peak excretion time, which was 0–5 h
for the group consuming a-rhamnosidase-treated juice (2)
and 5–10 h for (1) and (3) (Fig. 3).
Discussion
We show for the first time that naringenin-7-O-glucoside is
more bioavailable than narirutin (naringenin-7-O-rutinoside)
in human subjects. This is as judged by the total naringenin
AUC, Cmax and urinary excretion data that were significantly
higher for naringenin-7-O-glucoside compared with the
natural untreated orange juice containing narirutin. This is in
accordance with hesperetin(9) and quercetin(10). Others have
studied the bioavailability of naringenin in rats(21) where the
urinary naringenin recovery as percentage of dose was 28,
31, and 14 % after aglycone, glucoside or rhamnoglucoside
(naringin) intake, respectively. The urinary naringenin
recovery as percentage of dose in the present study was 7
and 47 % after narirutin and naringenin-7-O-glucoside
intake, respectively. When naringenin was given as an
aglycone to human volunteers, the urinary recoveries for
naringenin were approximately 6 % of the administered
dose, i.e. there was no increase in bioavailability (as observed
in rats)(22). It seems therefore that in human subjects
naringenin bioavailability is highest when consumed as a
monoglucoside. Higher bioavailability of monoglucosides
might provide health protective effects in lower doses since
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Fig. 1. Plasma concentration v. time curve of total naringenin in healthy
human subjects after consumption of two orange juice treatments. O, Natural
juice (1); B, a-rhamnosidase-treated juice (2). Values are means with their
standard errors, n 16 (1), n 15 (2).
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increased bioavailability of hesperetin-7-O-glucoside resulted
in the same level of protection against bone loss as compared
to higher levels of hesperidin (hesperetin-7-O-rutinoside) in
rats (0·25 and 0·5 % of the diet, respectively)(23).
Other studies on bioavailability of naringenin from orange
juice have reported values for relative urinary excretion
from 1 to 18 % of narirutin intake(11,24,25); the present study
on untreated orange juice for naringenin is in the middle of
this range. The biochemical pathway accounting for the
increased bioavailability of naringenin-7-O-glucoside has
been described in several papers. The absorption of flavonoid
glucosides in the small intestine is facilitated by the presence
of lactase phloridzin hydrolase in the gut lumen brush
border and b-glucosidase in the intestinal cells(12,13,26). Both
enzymes are capable of hydrolysing flavonoid glucosides
but not rutinosides, which are only absorbed after hydrolysis
by the colonic microflora.
We have found six hesperetin and two naringenin
metabolites in human urine after consumption of (1) natural
untreated orange juice; (2) a-rhamnosidase-treated orange
juice; (3) orange juice fortified with three times the original
content of hesperetin-7-O-rutinoside. We have identified the
exact site of conjugation and quantified several hesperetin
and both naringenin metabolites. Two recent studies have
identified hesperetin and naringenin metabolites in human
urine after consumption of orange juice(25,27). Both have
found hesperetin-7-O-glucuronide, naringenin-7- and -40-O-
glucuronide. Brett and co-workers have identified hesperetin-
30-O-glucuronide and hesperetin-30-O-sulphate as well. In
addition to these metabolites, we have further identified
hesperetin-5,7-O-diglucuronide and hesperetin-30,7-O-diglu-
curonide. All quantification of metabolites was based on the
corresponding metabolite either as synthetic standard or
collected directly from urine with high metabolite concen-
tration. This excludes a potential source of error from
quantitative estimates based on non-identical metabolites.
In the present study, glucuronides of hesperetin were the
most abundant metabolites recovered. This result is in
agreement with several other studies(11,25,28,29). We have
also found a substantial amount of hesperetin-30-O-sulphate
excretion after all treatments. It has been suggested that
flavonol sulphate-glucuronides are glucuronidated before
sulphation, and the sulphation then occurs in the liver(30,31).
In contrast, Jaganath et al. (32) did not find evidence of sulpha-
tion of quercetin after intervention with tomato juice
containing rutin (quercetin-3-O-rutinoside which is absorbed
in the colon), whereas quercetin-30-O-sulphate is one of the
dominating metabolites in plasma from human volunteers
fed fried onions (containing quercetin-40-O-glucoside and
quercetin-3,40-O-diglucoside which are absorbed in the small
intestine)(30,33). In the present study, the amount of hespere-
tin-30-O-sulphate in the urine was not affected by the site of
absorption indicating that either hesperetin can be sulphated
equally by both small intestinal and colonic sulphotransferases
or hesperetin sulphation predominantly occurs in the liver
after absorption. It has already been shown that liver cells
can deconjugate certain quercetin glucuronides and then
subsequently sulphate them(31).
The phase 2 enzymes, UDP glucuronosyl transferase and
sulphotransferase, catalyse the conjugation of polyphenols
with glucuronic acid and sulphate groups, respectively(16,34,35).
Both enzymes exist as numerous isoforms and are present in
several tissues including the small intestine, colon and
liver(36,37). Expression of both enzyme classes shows
common characteristics in the human alimentary tract;
however, the pattern of the forms expressed differs between
various segments and opens up the possibility that different
metabolites can be formed according to where in the alimen-
tary tract the aglycone is absorbed(36,37). The present study
provides no information on the mechanisms involved in con-
jugation of hesperetin and naringenin; however, it is evident
that following the release of aglycone, hesperetin and narin-
genin are subjected to glucuronidation and/or sulphation, and
Table 2. Pharmacokinetic measurements for total naringenin in healthy human subjects after the consumption of two orange juice treatments
(untreated (1) and a-rhamnosidase-treated (2))
(Mean values and standard deviations)
Untreated orange juice a-Rhamnosidase-treated orange juice
P value
Mean SD Mean SD
n 16 15
Ingested dose (mg/kg body weight) 0·83 0·52
AUC (0–600 min, mmol/l£ min) 18 12 70 29 ,0·0001
Cmax (mmol/l) 0·12 0·14 0·77 0·35 ,0·0001
Tmax (min) 311 183 93 166 0·002
Relative urinary excretion (% intake) 7 3 47 17 ,0·0001
AUC, area under the curve; Cmax, peak plasma concentration; Tmax, time to maximum plasma concentration.
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Fig. 2. Representative chromatogram of hesperetin and naringenin
metabolites in human urine 0–5 h after ingestion of a-rhamnosidase-treated
orange juice (2). (X) Hesperetin-30,7-O-diglucuronide, (IX) hesperetin-5,
7-O-diglucuronide, (XIV) hesperetin-sulphate-glucuronide, (XIII) naringenin-
7-O-glucuronide, (XII) naringenin 40-O-glucuronide, (VIII) hesperetin 7-O-
glucuronide, (VII) hesperetin 30-O-glucuronide, (XI) hesperetin 30-O-sulphate,
(IS1) internal standard 13C3 daidzein, (IS2) internal standard
13C3
O-desmethylangolensin.
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the pattern of excreted metabolites is not affected by the
site (small intestine or colon) of absorption. Furthermore,
increasing the dose of hesperidin 3-fold only affected the
total concentration but did not have any impact on the
profile of the conjugates formed after colonic absorption.
Colonic microflora produce lower molecular weight phenolics
that can be absorbed, such as dihydrocinnamic, phenylacetic
and benzoic acids. However, these have not been characterised
in the present study.
It is generally agreed that conjugate position is important
in relation to the biological activity of flavonoids in
human subjects, but only a few studies have looked at the
biological activities of the conjugates(38). Hesperetin glucu-
ronides, but not the hesperetin aglycone, protected against
UV-A-induced necrotic cell death(39). Quercetin glucuronides
inhibited Cu2þ-induced oxidation of human LDL(40).
Xanthine oxidase was inhibited by quercetin conjugates,
and the inhibition varied 50–800-fold depending on the
site of conjugation(41). Hesperetin aglycone protected against
oxidative injury to primary cortical neurons whereas
hesperetin-7-O-glucuronide did not(42), probably related to
the inability of glucuronide metabolites to passively traverse
membranes, unless a transporter is present(31). In general,
the responses to flavonoid conjugates are weaker than those
to the aglycones(38).
In conclusion, we have shown that the bioavailability of
naringenin-7-O-glucoside is increased about 4-fold based on
AUC compared to narirutin in healthy human subjects
consuming orange juice. There was no significant difference
between the pattern of metabolites excreted in urine after
consumption of orange juice containing either glucosides or
rutinosides, demonstrating that metabolism of hesperetin
and naringenin after absorption in the small intestine is not
significantly different from the metabolism after absorption
in colon. In addition, it was shown for hesperidin that a
3-fold increase in dose does not affect the pattern of excreted
metabolites. The eight identified metabolites were all phase 2
conjugates, of which seven were structurally elucidated.
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Fig. 3. Metabolite excretion in urine as percentage of intake. (a) Hesperetin
metabolites. , Hesperetin-7-O-glucuronide; , hesperetin-30-O-glucuronide;
A, hesperetin-sulphate-glucuronide; , hesperetin-30-O-sulphate. (b) Narin-
genin metabolites. A, Naringenin-40-O-glucuronide; , naringenin-7-O-
glucuronide. Metabolites were measured in urine collected at the peak
excretion time, which was 0–5 h for the a-rhamnosidase-treated juice (2) and
5–10 h for the natural (1) and the fortified juice (3). Means with their standard
errors, n 13 (2 and 3), n 15 (1).
Table 3. 1H NMR, LC–MS and UV data of hesperetin and naringenin metabolites excreted in human urine after consumption of three different kinds
of orange juice (see Table 1 and Fig. 2)
Compound number VII VIII IX X XI XII XIII XIV
C(2)H 5·42 (d) 5·46 (d) 5·44 (d) 5·51 (d) NO 5·47 (d) NO NO
C(3)Ha 3·19 (dd) 3·21 (dd) 3·03 (dd) NO NO 3·18 (dd) NO NO
C(3)Hb 2·71 (d) 2·76 (d) 2·69 (d) 2·74 (d) NO 2·73 (d) 2·73 (s) NO
GlcCa(H) 5·12 (d) 5·12 5·12, 4·98 5·13 (d), 4·62 (ad) NO 5·05 (d) 5·13 NO
C(2,3,4) 3·55–3·25 3·55–3·25 3·55–3·25 4·1–3·25# NO 3·55–3·25 4·3–3·15 NO
C(5) 3·88 (d) 3·98 3·98, 3·95 NO 3·9 4·3–3·15 NO
H6 5·88 (s) 6·12 6·41 6·15 (s) NO 5·90 (s) 6·14 (s) NO
H8 5·91 (s) 6·18 6·45 (s) 6·20 (s) NO 5·88 (s) 6·18 (s) NO
20 7·25 (s) 6·93 (s) 6·92 (s) 7·27 NO 7·43 7·3 NO
30 7·05 7·79
40 3·77 3·75 3·75 3·77 NO NO
50 6·99 (d) 6·86 (d) 6·86 (d) 6·99 NO 7·05 7·79 NO
60 7·09 (d) 6·90 (d) 6·89 (d) 7·11 NO 7·43 7·3 NO
[M 2 H]2 (m/z) 477 477 653 653 381 447 447 557
FI (m/z) 301 301 477, 301 477, 301 301 271, 151 271, 151 477, 381, 301
UV abs (nm) 288 284 ND ND 288 290 282 282
d, Doublet; NO, not observed; dd, double doublet; ad, apparent doublet; #, multiplet; s, singlet; FI, fragment ion(s); ND, not detected; UV abs, UV absorption.
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